Ivermectin, Mebendazole and Fenbendazole for Breast Cancer: A Structured Case-Series Analysis of 130 Reports

Abstract

Background: Fenbendazole, mebendazole and ivermectin have attracted interest as potential repurposed agents in oncology. Laboratory and preclinical studies provide biologically plausible mechanisms, but evidence for clinical efficacy in breast cancer remains insufficient for these drugs to be considered established anticancer treatments.

Objective: This review restructures a publicly assembled archive of 130 breast-cancer case narratives into a hierarchical case-series classification system designed to identify recurring clinical patterns, sub-patterns, treatment combinations, metastatic distributions and reported response phenotypes.

Methods: The archive was coded according to disease stage, recurrence status, breast-cancer subtype when reported, metastatic site, repurposed-drug exposure, conventional co-treatment, additional interventions, reported response and degree of objective verification. Cases were also classified according to whether the observed response could reasonably be attributed to the repurposed drug, a combination treatment, or remained indeterminate.

Results: The archive demonstrates several recurring patterns: early-stage tumor shrinkage before surgery; metastatic disease with radiographic regression; bone-dominant metastatic responses; nodal responses; liver and lung responses; CNS/brain responses; tumor-marker reductions; pathological complete responses following multimodal treatment; and patient-reported clinical improvement. A major recurring sub-pattern is concurrent use of ivermectin or a benzimidazole with chemotherapy, endocrine therapy, targeted therapy or antibody-drug conjugates. Consequently, many reported responses cannot be causally attributed to ivermectin, mebendazole or fenbendazole alone.

Conclusions: The archive is best interpreted as a hypothesis-generating case registry rather than proof of treatment efficacy. The strongest research signal is not that the 130 reports establish efficacy, but that they identify recurring response phenotypes and treatment combinations that could be investigated prospectively. Controlled clinical trials, prospective registries, standardized imaging, pathology review, biomarker documentation and adverse-event reporting are required.

Important evidence qualification: This is a structured analysis of publicly reported cases and testimonials, not a prospective clinical trial. The archive contains heterogeneous sources, including patient narratives, practitioner-shared cases and at least one published peer-reviewed case report. Many reports lack complete pathology, imaging, molecular subtype, treatment chronology or independent verification. Therefore, the number "130" should not be interpreted as 130 independently validated clinical cases.

1. Introduction and Research Question

Breast cancer remains one of the most challenging and prevalent malignancies worldwide, with metastatic and treatment-resistant cases posing significant therapeutic hurdles. Conventional treatment options, including chemotherapy, targeted therapies, and immunotherapy, often reach their limits, particularly in advanced stages such as triple-negative breast cancer (TNBC).

For patients with actionable mutations identified through molecular profiling, targeted therapies are the preferred treatment approach. In particular, for estrogen receptor–positive (ER+) breast cancer patients with a low Oncotype DX recurrence score, hormonal therapy alone is often appropriate, as genomic testing indicates a low risk of cancer recurrence and supports de-escalation of more aggressive systemic treatments.


The preference for targeted treatments reflects their demonstrated efficacy in improving outcomes in these molecularly defined subgroups, underscoring the importance of comprehensive genomic profiling in guiding personalized therapy decisions. However, targeted agents are only applicable to small patient subsets.

Triple-negative breast cancer (TNBC) lacks estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, representing 10–15% of breast cancers with an aggressive clinical course and poor metastatic survival (~11–13 months median OS) [1–3]. Immune checkpoint inhibitors (ICIs) such as pembrolizumab and balstilimab have conferred survival gains but durable responses remain uncommon [4–6].

In recent years, interest has grown in the potential role of drug repurposing—utilizing existing, FDA-approved medications originally designed for other indications—to augment cancer treatment.

Among repurposed agents, fenbendazole, ivermectin, and mebendazole have garnered attention for their promising anticancer properties demonstrated in both preclinical studies and clinical anecdotes. These benzimidazole-class drugs, traditionally used as antiparasitic agents, exhibit mechanisms that may inhibit tumor growth, induce cancer cell death, and enhance immune responses against malignancies.

This article presents a compilation of more than 100 compelling case reports showcasing remarkable responses in breast cancer patients treated with these repurposed drugs, often in combination with standard therapies or immunomodulators. These success stories highlight the potential of integrative oncology approaches to improve outcomes in patients with limited conventional options, warranting further rigorous investigation and clinical integration.

The central question is not simply:

"Do ivermectin, mebendazole or fenbendazole work for breast cancer?"

A more scientifically useful question is:

"What recurring clinical and treatment-response patterns appear within the publicly reported breast-cancer cases involving these agents, and which patterns are sufficiently well documented to justify prospective investigation?"

This distinction is critical because a heterogeneous case archive can generate hypotheses but cannot establish efficacy, comparative effectiveness or causality.

2. Case-Series Classification Framework

P1 — Primary tumor response Tumor shrinkage or disappearance in the breast.
P2 — Nodal response Regression or disappearance of regional or distant lymph-node disease.
P3 — Bone response Healing, sclerosis, metabolic resolution or reported disappearance of osseous metastases.
P4 — Visceral response Liver, lung, pleural, adrenal or other visceral disease regression.
P5 — CNS response Brain or leptomeningeal disease improvement.
P6 — Biomarker response Reduction in CEA, CA15-3, CA27-29, CA125, ctDNA or related markers.
P7 — Pathological response No residual invasive cancer reported at surgery.
P8 — Clinical response Improved pain, mobility, breathing, performance status or other symptoms.

Sub-pattern classification

  • S1 — Early-stage response: apparent regression before definitive surgery.
  • S2 — Neoadjuvant combination: repurposed agents used alongside chemotherapy or targeted therapy before surgery.
  • S3 — Metastatic combination: repurposed agents added to an established metastatic regimen.
  • S4 — Repurposed-drug predominant: no major concurrent conventional systemic treatment documented.
  • S5 — Treatment-resistant disease: progression or failure of one or more conventional therapies before the reported response.
  • S6 — Recurrence: disease returning after a previous remission or definitive treatment.
  • S7 — CNS-dominant: brain or leptomeningeal disease is a defining feature.
  • S8 — Bone-dominant: osseous disease is the dominant metastatic phenotype.
  • S9 — Visceral-dominant: liver/lung/pleural or other visceral disease dominates.
  • S10 — Multisite metastatic: several metastatic compartments involved simultaneously.
  • S11 — Biomarker-led: principal evidence is a tumor-marker or ctDNA change.
  • S12 — Symptom-led: principal evidence is clinical improvement rather than imaging/pathology.

3. Evidence-Verification Hierarchy

Tier Definition Interpretation
E5 Independent pathology plus serial imaging and/or molecular confirmation Highest evidentiary value within this archive, but still not equivalent to a controlled trial
E4 Pathology or surgery plus objective imaging Strong individual-case documentation
E3 Serial imaging, PET/CT, MRI or CT objectively described Objective response signal; attribution remains uncertain
E2 Biomarker plus clinical/imaging information Supportive but incomplete
E1 Clinical or symptom improvement without adequate objective verification Hypothesis-generating
E0 Insufficient information or testimonial only Cannot independently establish response

4. Attribution Framework

Each case should be interpreted according to the following causal-attribution hierarchy:

  1. A1 — Repurposed-agent predominant: little or no major concurrent anticancer treatment documented.
  2. A2 — Combination response: repurposed agent plus conventional treatment.
  3. A3 — Sequential response: conventional treatment followed by addition of repurposed therapy.
  4. A4 — Multiple-intervention response: repurposed drugs plus supplements, diets, metabolic therapies or other interventions.
  5. A5 — Indeterminate: chronology or treatment exposure is insufficient to determine attribution.

This framework prevents a common analytical error: treating temporal association as proof that the repurposed drug caused the response.

5. Full 130-Case Classification Matrix

Reading the matrix: "NR" means the source archive does not provide sufficient information for reliable classification. This is intentional. Missing data should remain missing rather than being inferred.

⇔ Swipe to see the full table

Case Stage Biology / subtype Metastatic pattern Repurposed intervention Co-treatment / context Reported response phenotype Evidence
1IVNRNodes + bone + marrowFenbendazole-based protocolHormone blocker; supplementsReported NED after ~1 yearE2
2IVNRNodes + liver + boneNRNRCase narrative; outcome incompletely documentedE0
3IVER+/PR+/HER2−BoneFenbendazole + ivermectinFulvestrant + ribociclib + letrozoleCA27-29 remission; PET NED reportedE3
4IVNRBone + pleuraIvermectinDCA + omeprazole + tamoxifenPleural stabilization; marker reductionE3
5IVNRBoneFenbendazoleNRReported NED; marker/imaging improvementE2
6II→IVNRPleura + lung + nodesIvermectin + fenbendazoleMultiple supplements/metabolic therapiesReported metabolic/radiographic NED; toxicity episodeE3
7IVNRBone + brainIvermectin + fenbendazoleLactoferrinClinical/QOL improvementE1
8IVNRNRNRNRInsufficiently documented archive caseE0
9IVHER2-related treatment contextLiver + boneIvermectin + mebendazoleEnhertuCEA reductionE2
10IVNRMetastaticFenbendazole + intermittent ivermectinNRReported cancer-free intervalE1
11IVTriple-positiveLung + bone + nodesIvermectin + mebendazolePrevious conventional therapy; mastectomyPET reported NEDE3
12RecurrentNRMultiple breast masses + neck nodesIvermectin + mebendazoleNo chemo/radiation reportedMultiple lesions and nodes regressedE2
13IVER+/PR+/HER2−SpineIvermectin + fenbendazoleNo current chemotherapy reportedPET NED reportedE3
14IVTNBCLungFenbendazole + ivermectin + mebendazoleNRReported NED after ~1 yearE1
15IIITNBCRegional nodesFenbendazoleNo other treatment reportedClinical regression; cancer-free claimE1
16NRNRNRNRNRInsufficient informationE0
17IVER+/PR+/HER2−Bone + liver + lung + ascitesRepurposed protocolHospice context; conventional therapy declinedReported clinical/radiographic responseE3
18NRNRNRNRNRArchive narrativeE0
19NRNRNRNRNRArchive narrativeE0
20IVNRMultiple breast lesions + cervical nodesIvermectin + mebendazoleNo chemo/radiation reportedMultiple lesions/nodes reportedly disappeared or shrankE2
21NRNRNRNRNRArchive narrativeE0
22NRNRNRNRNRArchive narrativeE0
23NRNRNRNRNRArchive narrativeE0
24NRNRNRNRNRArchive narrativeE0
25NRNRNRNRNRArchive narrativeE0
26NRNRNRNRNRArchive narrativeE0
27NRNRNRNRNRArchive narrativeE0
28NRNRNRNRNRArchive narrativeE0
29NRNRNRNRNRArchive narrativeE0
30NRNRNRNRNRArchive narrativeE0
31NRNRNRNRNRArchive narrativeE0
32NRNRNRNRNRArchive narrativeE0
33NRNRNRNRNRArchive narrativeE0
34NRNRNRNRNRArchive narrativeE0
35IVTNBCBrain + lungIvermectin + mebendazolePrevious/concurrent conventional treatmentBrain and lung lesions reportedly shrinkingE3
36IVNRSpineNRNRReported improvementE1
37IIINRAxillary nodesIvermectin + mebendazoleProceeding to surgeryPrimary tumor ~82% shrinkage; nodal resolution reportedE3
38NRNRBreast massTopical ivermectinBiopsy plannedMass reportedly disappeared before biopsyE1
39IVNRBrain + lungIvermectin + mebendazoleCBDBrain lesions reportedly reduced; up to ~96% calculated volume reductionE3
40IIINRAxillary nodesIvermectin + fenbendazole → mebendazoleNRPrimary mass markedly reduced; nodes resolvedE3
41IVNRBoneIvermectin + mebendazoleCBD>50% breast-mass reduction reportedE3
42IVNRNodes + T11 soft tissueIvermectin + fenbendazoleNRPrimary mass and nodes substantially reducedE3
43IITNBCRegional nodesIvermectin + mebendazoleChemotherapyPathology reportedly showed no residual cancerE4
44IVNRChest wallIvermectin + mebendazole + topical ivermectinDMSO + castor oil + red lightChest-wall improvement and lesion shrinkage reportedE2
45IVNRNRNRNRReported responseE1
46IVNRBrainNRNRBrain metastasis response reportedE2
47NRNRNRNRNRArchive narrativeE0
48IVNRMetastaticNRPublished case reportPeer-reviewed individual case reportE4
49IVNRBrain + nodes + boneIvermectin + mebendazoleDMSOMultiple brain lesions reduced; symptoms improvedE3
50ITNBC, grade 3Regional diseaseIvermectin + mebendazoleChemotherapy + surgeryNo residual cancer on pathology reportedE4
51EarlyNRPrimary breast tumorIvermectin + mebendazoleNo chemotherapy reported5.2 cm → 1.8 cm reportedE3
52IVNRBoneIvermectin + fenbendazoleNo chemotherapy reportedMarker reduction; bone healing; pleural improvementE3
53IVNRBone + liverIvermectin + mebendazoleNRctDNA/biomarker and imaging improvement reportedE2
54IVNRNodes + boneIvermectin + mebendazoleNRTumor regression reportedE2
55NRNRNRNRNRArchive narrativeE0
56IVNRMultisiteIvermectin + fenbendazole + mebendazoleNRMultisite improvement reportedE2
57IVNRThoracic + abdominal nodesIvermectin + fenbendazoleEnhertuPET NED; CEA 25 → 1.4 reportedE3
58IVNRNodes + boneIvermectin + mebendazoleNRResponse reported after ~3 monthsE2
59IER+/PR+/HER2−Primary tumorIvermectin + fenbendazole → mebendazoleSurgeryNo residual cancer on lumpectomy pathology reportedE4
60IVNRMetastaticIvermectin + fenbendazoleNRRemission reported after ~11 monthsE2
61NRNRNRNRNRArchive narrativeE0
62IVNRBoneIvermectin + mebendazoleConventional treatment contextMetastatic response reportedE3
63RecurrentNRAxillary nodeIvermectin + mebendazoleLetrozole~90% nodal regression reportedE3
64IVNRAxilla + lungIvermectin + mebendazoleChemotherapy + mastectomyNo tumor found at surgery reportedE4
65IVMale breast cancerLungIvermectin + mebendazoleNRLung metastases shrinkingE3
66IVNRBoneIvermectin + fenbendazoleNRBone response reportedE3
67IIITNBCRegionalIvermectin + fenbendazoleConventional treatment contextMRI NED reportedE3
68IVTNBCNRIvermectin + albendazoleNRPathology/biology change reportedE2
69IVNRNRNRAfter ribociclib failureResponse reportedE2
70IVTNBCBrainIvermectin + mebendazoleNRBrain and systemic tumors reportedly shrinkingE3
71EarlyTNBCPrimary tumorIvermectin + mebendazoleNRTumor regression reportedE2
72IIIGrade 34 lymph nodesRepurposed-drug protocolNo conventional therapy reportedCancer-free claim after >1 yearE1
73IIINRRegional nodesNRNRResponse reportedE2
74IVNRBoneIvermectin + mebendazoleEnhertuMost bone lesions reportedly healed/resolvedE3
75IVNRNodal metastasisIvermectin + mebendazoleNR2.5 cm → 0.8 cm; ctDNA reportedly negativeE3
76IIINRNRNRNRReported responseE1
77IVNRBoneIvermectin + mebendazoleModified citrus pectinCA27-29 decline; PET bone improvementE3
78IVNRMetastaticIvermectin + mebendazoleNR2.5 cm metastasis reportedly disappearedE3
79IVNRMetastaticNRNRReported responseE1
80NRNRNRNRNRArchive narrativeE0>
81NRNRNRNRNRArchive narrativeE0
82NRNRNRNRNRArchive narrativeE0
83NRNRNRNRNRArchive narrativeE0
84NRNRNRNRNRArchive narrativeE0
85NRNRNRNRNRArchive narrativeE0
86NRNRNRNRNRArchive narrativeE0
87NRNRNRNRNRArchive narrativeE0
88NRNRNRNRNRArchive narrativeE0
89NRNRNRNRNRArchive narrativeE0
90NRNRNRNRNRArchive narrativeE0
91NRNRNRNRNRArchive narrativeE0
92NRNRNRNRNRArchive narrativeE0
93NRNRNRNRNRArchive narrativeE0
94NRNRNRNRNRArchive narrativeE0
95NRNRNRNRNRArchive narrativeE0
96NRNRNRNRNRArchive narrativeE0
97NRNRNRNRNRArchive narrativeE0
98NRNRNRNRNRArchive narrativeE0
99NRNRNRNRNRArchive narrativeE0
100NRNRNRNRNRArchive narrativeE0
101NRNRNRNRNRArchive narrativeE0
102NRNRNRNRNRArchive narrativeE0
103NRNRNRNRNRArchive narrativeE0
104NRNRNRNRNRArchive narrativeE0
105NRNRNRNRNRArchive narrativeE0
106NRNRNRNRNRArchive narrativeE0
107NRNRNRNRNRArchive narrativeE0
108NRNRNRNRNRArchive narrativeE0
109NRNRNRNRNRArchive narrativeE0
110NRNRNRNRNRArchive narrativeE0
111NRNRNRNRNRArchive narrativeE0
112NRNRNRNRNRArchive narrativeE0
113NRNRNRNRNRArchive narrativeE0
114NRNRNRNRNRArchive narrativeE0
115NRNRNRNRNRArchive narrativeE0
116NRNRBreast + neck massesIvermectin + mebendazoleReported patient series contextClinical benefit / NED claims reportedE1
117IVNRLeptomeningealIvermectin + mebendazoleNRImprovement reported after ~10 monthsE2
118NRNRNRNRNRArchive narrativeE0
119IVNRLiver + gallbladderIvermectin + fenbendazoleAfter ribociclib failureRemission reported after 2 monthsE3
120IVNRLiver + nodes + pleura + boneIvermectin + mebendazoleEribulinMultisite metastatic regressionE3
121IVNRBoneIvermectin + fenbendazoleRibociclibNear-remission reportedE3
122IIINRBreast + lymph nodeIvermectin + mebendazoleNo conventional treatment reportedBoth tumors reportedly reducedE2
123EarlyNRPrimary breast diseaseIvermectin + mebendazoleNRMRI NED after ~12 months reportedE3
124Early / recurrent focusNRSecond breast focusIvermectin + mebendazolePrior surgery; radiation/hormone therapy declinedCancer-free claim after 3 monthsE2
125IVTNBCLung + adrenal + bone + liver + nodesIvermectin + mebendazole + fenbendazoleAbraxaneMultisite regression; most disease reportedly resolvedE3
126IVNRAxillary node + boneIvermectin + mebendazole/fenbendazoleNo conventional treatment reportedNodal improvement; no metabolically active bone disease reportedE3
127IVNRGallbladder + liverIvermectin + fenbendazoleHerceptin + EnhertuLarge lesion and liver disease reportedly disappearedE3
128EarlyTNBC, poorly differentiated, Ki-67 highPrimary breast tumorIvermectin + mebendazoleAdriamycin/Cytoxan/Keytruda → Taxol/Carboplatin/KeytrudaPathology reportedly showed no residual diseaseE4
129IVNRBoneFenbendazole + ivermectin + modified citrus pectinNRCEA 21 → 2.9; bone lesions reportedly resolved/healedE3
130IVNRBone + lungIvermectin + mebendazolePhesgo + paclitaxel + carboplatinRemission reported after ~6 monthsE3
Matrix limitation: The archive contains uneven documentation. The matrix deliberately marks incompletely documented cases as NR rather than manufacturing subtype, metastatic-site or treatment information. This makes the classification more reproducible and prevents false precision.

6. Pattern Analysis of the Archive

Pattern 1 — Combination therapy is the dominant recurring phenotype

The most important pattern is the frequency with which ivermectin, mebendazole or fenbendazole appear alongside conventional oncology treatment.

Examples include chemotherapy, endocrine therapy, CDK4/6 inhibition, antibody-drug conjugates and HER2-directed therapy. Cases 9, 43, 50, 57, 64, 74, 120, 125, 127, 128 and 130 illustrate this pattern particularly clearly.

This creates a major causal problem. A response observed after combination treatment demonstrates that the patient improved after receiving the combination. It does not demonstrate that the repurposed drug caused the response or that the combination is superior to conventional therapy alone.

Research implication: combination cases are not weak evidence; they are simply evidence for a different question: whether repurposed drugs may modify or complement established therapy.

Pattern 2 — Early-stage tumors frequently appear in a neoadjuvant-response pattern

Several reports describe measurable breast-tumor shrinkage before surgery, followed by lumpectomy or mastectomy showing little or no residual invasive disease.

Cases 43, 50, 59, 64 and 128 are particularly relevant to this pattern.

However, where chemotherapy, immunotherapy or targeted therapy was administered concurrently, the pathology response cannot be attributed to the repurposed drugs alone.

The most scientifically useful future design would therefore be a prospective neoadjuvant observational study with:

  • pretreatment biopsy;
  • molecular subtype;
  • baseline MRI;
  • standardized treatment chronology;
  • serial imaging;
  • documented repurposed-agent exposure;
  • surgical pathology;
  • residual cancer burden score; and
  • ctDNA where appropriate.

Pattern 3 — Bone-dominant metastatic disease is a recurring sub-pattern

Bone metastases appear repeatedly throughout the archive, including cases 3, 5, 17, 52, 53, 62, 66, 74, 77, 121, 126 and 129.

The reported responses include increased sclerosis/healing, reduced metabolic activity, reduction in tumor burden and, in some narratives, apparent resolution.

Bone disease requires particular caution because radiographic sclerosis can represent healing, treatment response or altered lesion biology. Therefore, "healed bone metastases" should not automatically be coded as complete eradication of viable cancer.

Pattern 4 — CNS disease creates a distinct hypothesis-generating cluster

Cases involving brain or leptomeningeal disease include cases 7, 35, 39, 46, 49, 65, 70 and 117.

These reports are potentially important because CNS penetration is a mechanistic question that cannot be answered from testimonials alone.

The appropriate prospective endpoint would be standardized brain MRI using accepted response criteria, rather than subjective descriptions such as "brain lesions are better."

Pattern 5 — Biomarker responses frequently accompany imaging responses

Several reports describe reductions in CEA, CA15-3, CA27-29, CA125 or ctDNA together with imaging findings.

Biomarker reductions are potentially useful corroborating evidence but should not be treated as synonymous with tumor eradication. Tumor markers can change for reasons unrelated to durable disease control.

Pattern 6 — The archive contains a treatment-resistant disease subgroup

A recurring sub-pattern involves disease progression after conventional treatment followed by addition of repurposed agents.

Cases 69, 119 and 121 are representative of this pattern.

This creates an important hypothesis: whether repurposed drugs might have activity in tumors that have developed resistance to a conventional pathway-directed therapy.

It also creates substantial selection bias because patients who experience unusually favorable outcomes are more likely to be reported than patients who experience no benefit.

Pattern 7 — "No conventional treatment" is an important but small and highly confounded subgroup

Cases 12, 20, 51, 52, 72, 122 and 126 contain reports of little or no conventional systemic therapy.

These cases are particularly interesting for hypothesis generation because the attribution problem is somewhat smaller. However, they remain vulnerable to diagnostic uncertainty, spontaneous fluctuations, incomplete documentation, selection bias and inaccurate reconstruction of the treatment timeline.

They should therefore be treated as candidates for formal case reports rather than proof of efficacy.

Pattern 8 — Multi-agent "integrative protocols" create an attribution problem

Some cases involve ivermectin/fenbendazole/mebendazole plus multiple supplements, dietary interventions, metabolic therapies, topical preparations or other agents.

Such cases may represent a genuine systems-medicine approach, but they cannot identify which component produced the response.

The appropriate classification is therefore A4 — multiple-intervention response.

7. Sub-Pattern Map

Sub-pattern Clinical phenotype Typical archive signal Main limitation Best future study
S1 Early-stage tumor shrinkage Smaller tumor before surgery Natural history / conventional therapy Prospective neoadjuvant study
S2 Pathological response after combination No residual disease at surgery Attribution to combination impossible Controlled neoadjuvant trial
S3 Metastatic combination response Imaging improvement after adding repurposed drugs Confounding by concurrent therapy Randomized add-on trial
S4 Repurposed-drug predominant response Little/no conventional treatment Selection and diagnostic bias Prospective registry
S5 Response after treatment resistance Progression followed by response Regression to mean and treatment switching Biomarker-defined trial
S6 Recurrence response Recurrent disease subsequently regresses Heterogeneous biology Longitudinal registry
S7 CNS response Brain/leptomeningeal improvement Need standardized MRI criteria CNS-specific trial
S8 Bone response Healing/sclerosis/metabolic resolution Bone imaging interpretation Serial PET/CT + MRI
S9 Visceral response Liver/lung regression Concurrent therapy often present RECIST-based study
S10 Multisite response Several organs improve simultaneously Multiple treatment components Prospective multimodal cohort
S11 Biomarker response CEA/CA15-3/CA27-29/ctDNA decline Surrogate endpoint Biomarker-linked trial
S12 Symptom/QOL response Pain, mobility, breathing improve Subjective endpoint Validated PRO instruments

8. The Most Important Cross-Case Signal: Treatment Synergy Hypothesis

The archive repeatedly contains the same temporal structure:

Conventional therapy → repurposed agent added → subsequent improvement.

This is scientifically different from claiming:

Repurposed agent → cancer response.

The first observation supports a combination-therapy hypothesis. The second would require evidence that isolates the repurposed agent.

This distinction should become a central principle of the article.

9. What the 130 Cases Do and Do Not Demonstrate

Question What the archive supports What it does not establish
Are responses reported? Yes. Multiple response phenotypes are repeatedly described. That all reported responses are independently verified.
Are responses seen in metastatic disease? Yes. That metastatic disease is reliably controlled by these drugs.
Are responses seen in TNBC? Yes, including several reported responses. That these drugs are effective against TNBC.
Are responses seen with chemotherapy? Yes. That the repurposed drugs caused the response.
Are responses reported without chemotherapy? Yes. That chemotherapy-free treatment is equivalent or superior.
Are pathological responses reported? Yes. That repurposed drugs alone caused those pathological responses.
Are brain responses reported? Yes. That CNS efficacy has been established.
Are long-term responses reported? Yes, including multi-year narratives. Population-level survival benefit.
Is there proof from randomized breast-cancer trials? No. Clinical efficacy as standard breast-cancer treatment.

10. Major Sources of Bias

  • Selection bias: dramatic responders are more likely to be published or shared.
  • Publication bias: unsuccessful cases may never enter the archive.
  • Attribution bias: multiple therapies are frequently used simultaneously.
  • Verification bias: some reports lack independent pathology or imaging review.
  • Recall bias: retrospective patient narratives may reconstruct events inaccurately.
  • Reporting bias: treatment dose, duration and chronology are inconsistently documented.
  • Confounding by conventional treatment: chemotherapy, endocrine therapy and targeted therapies may themselves produce major responses.
  • Confounding by natural disease variability: tumor markers and imaging can change over time.
  • Diagnostic uncertainty: some masses were not biopsy-confirmed.
  • Survivorship bias: long-term successful cases receive disproportionate attention.

11. Safety Signal: The Archive Should Not Be Read as a Dosing Guide

Do not use the doses reported in individual testimonials as a recommended cancer-treatment regimen.

Ivermectin and mebendazole are human medicines with established antiparasitic indications, but their use in cancer remains investigational. Fenbendazole is a veterinary antiparasitic and is not an approved human cancer treatment.

The archive itself contains examples of adverse effects and treatment interruptions, including liver-enzyme abnormalities and other toxicity concerns. The existence of apparently successful cases does not establish that a particular dose is safe or effective.

12. Proposed Prospective Study Design

The case archive can be converted from an anecdotal repository into a scientifically useful prospective research platform.

Minimum data set

  • Age and sex
  • Histological diagnosis
  • ER status
  • PR status
  • HER2 status
  • Grade
  • Ki-67 when available
  • TNBC status
  • Stage
  • Metastatic sites
  • Prior systemic therapies
  • Reason for treatment change
  • Repurposed agent and formulation
  • Start and stop dates
  • Concurrent anticancer therapy
  • Other supplements/interventions
  • Baseline imaging
  • Serial imaging
  • RECIST response where applicable
  • Pathological response where surgery occurs
  • ctDNA where available
  • CA15-3 / CA27-29 / CEA where clinically appropriate
  • Adverse events
  • Progression-free survival
  • Overall survival
  • Patient-reported outcomes

13. Proposed Evidence Upgrade for Future Cases

Current testimonial Upgrade
"Tumor disappeared" Pre/post MRI or CT with radiology report
"Cancer free" Pathology, PET/CT, MRI and/or validated disease-status assessment
"Tumor marker dropped" Serial standardized laboratory measurements plus imaging
"Bone metastases healed" Serial PET/CT/MRI and radiologist assessment
"Brain lesions shrank" Standardized brain MRI and accepted CNS response criteria
"Treatment synergy" Document exact treatment chronology and ideally compare with matched controls
"No chemotherapy" Document all systemic and local therapies to establish true exposure

14. Research Priorities

  1. Randomized add-on trials: conventional therapy versus conventional therapy plus ivermectin or a benzimidazole.
  2. Neoadjuvant breast-cancer studies: objective assessment of pathological response.
  3. TNBC studies: particularly treatment-resistant metastatic disease.
  4. CNS studies: brain-metastasis and leptomeningeal disease cohorts.
  5. Biomarker studies: identify molecular phenotypes associated with response.
  6. Drug-interaction studies: determine whether these agents alter pharmacokinetics or pharmacodynamics of established breast-cancer treatments.
  7. Safety registries: systematically record hepatic, neurological, gastrointestinal and other adverse events.

15. Overall Interpretation

The 130-case archive is more useful when treated as a pattern-discovery dataset than as a collection of "success stories."

The recurring signals can be summarized as follows:

Signal A Repeated tumor-regression narratives occur across early-stage and metastatic disease.
Signal B Bone, nodal and visceral responses recur across multiple cases.
Signal C CNS responses represent a potentially important but insufficiently validated subgroup.
Signal D Combination therapy is extremely common, making causal attribution difficult.
Signal E Some cases contain objective imaging or pathology, while others are primarily testimonial.
Signal F Treatment-resistant disease appears repeatedly and deserves prospective investigation.

Accordingly, the strongest scientifically defensible conclusion is:

The archive generates a clinically interesting hypothesis, not a proven treatment.

Repeated reports of objective tumor regression, pathological response, biomarker improvement and clinical benefit justify further investigation. They do not establish that ivermectin, mebendazole or fenbendazole independently treat breast cancer, nor do they establish an appropriate dose, safety profile or survival benefit.

16. Bottom Line for Patients

Patients should not substitute an unproven antiparasitic regimen for evidence-based breast-cancer treatment on the basis of testimonials.

The most responsible interpretation of these cases is that they identify potential research signals that deserve rigorous testing.

For patients interested in complementary or repurposed approaches, the safest framework is to discuss all non-standard treatments with the oncology team, document every intervention and avoid allowing an experimental therapy to delay treatments with established survival benefit.

17. Discussion

The fenbendazole and ivermectin cancer protocol gained rapid interest over the past years following some advanced cancer success stories (more than 700 case reports in more than 20 cancer types).

The breast cancer case reports and preliminary clinical findings presented in this article offer compelling real-world evidence supporting the potential role of repurposed antiparasitic drugs—fenbendazole, ivermectin, and mebendazole—in the management of breast cancer, including advanced and metastatic stages. Numerous anecdotal testimonials reveal significant tumor regression, symptom improvement, and in some cases, complete metabolic responses within remarkably short timeframes. Such dramatic outcomes are particularly notable considering these patients often had exhausted conventional treatment options or had tumors lacking actionable mutations.

While anecdotes suggest promise, experts emphasize no proven benefits in controlled trials, and self-use might risk delaying proven treatments. Ongoing research shows potential but needs randomised controlled trials (RCTs). 

Nevertheless, the evidence currently remains largely observational and anecdotal, lacking large-scale randomized controlled trials (RCTs) which remain the gold standard for clinical validation. Barriers to conducting such trials include limited financial incentives for off-patent drugs, regulatory complexities, and the dissonance between integrative and mainstream oncology. Consequently, adoption of these drugs in routine oncologic practice remains minimal, with skepticism persisting among many oncologists due to absence of robust, high-level evidence.

In light of these challenges, these repurposed drugs should be considered as adjuncts within comprehensive, individualized treatment protocols overseen by knowledgeable integrative oncology practitioners. Patient selection, dosing strategies, and monitoring protocols require further refinement through well-designed prospective registries and pragmatic clinical studies.

It is also essential to underscore that repurposed drug protocols should never replace standard-of-care cancer therapies but rather aim to complement them, potentially enhancing efficacy and reducing toxicity. Furthermore, integrative approaches incorporating diet, lifestyle optimization, and targeted supplementation may synergistically support therapeutic outcomes.

Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A 2025 Systematic Review

A total of 45 randomized controlled trials (RCTs) were included in this systematic review. Overall, supplementation was not associated with serious adverse events in the included trials. Vitamin D supplementation showed promise in some studies, with potential immunomodulatory and antioxidant effects, particularly when combined with other interventions. 

Omega-3 fatty acids and beta-glucan demonstrated potential in alleviating certain symptoms and improving quality of life. Studies on amino acids like acetyl-L-carnitine and L-arginine also yielded mixed results. Beta-glucan exhibited potential for immune-enhancing effects, while melatonin and creatine showed limited or no benefit for fatigue or muscle strength. Herbal extracts, including silymarin, curcumin, and EGCG, had varied effects. Curcumin studies presented mixed results. Silymarin showed potential for hepatoprotective effects.

Ketogenic metabolic therapy on patients with breast cancer: A randomized controlled clinical trial

In a study published in the Clinical Nutrition journal (2021), 80 patients with locally advanced and metastatic breast cancer were randomly assigned to a ketogenic diet or a control group for a 12-week treatment test. Patients in the ketogenic diet group had lower serum insulin levels, and their tumors shrank [Clinical Nutrition 2021].

How Vitamin D Supports Breast Cancer Prevention

Do the protective effects of vitamin D hold up across different populations, and what biological mechanisms explain them? A comprehensive review in Nutrients (2024) set out to answer both. The studies analyzed involved adult women across different age groups, geographic regions, and health statuses, including women with newly diagnosed breast cancer and healthy controls.

Across this diverse population, a consistent pattern emerged: women with higher blood vitamin D levels showed lower breast cancer risk, while deficiency appeared frequently among those diagnosed with the disease. This reinforces that vitamin D status matters across life stages, not only after illness appears.

Ivermectin inhibits epithelial-to-mesenchymal transition via Wnt signaling in endocrine-resistant breast cancer cells

In 2025 (Rujimongkon et al) - Researchers tested Ivermectin on lab-grown breast cancer cells, specifically types that no longer respond to hormone therapies (like tamoxifen or fulvestrant). It may help overcome drug resistance: When combined with tamoxifen (a standard hormone therapy), lower doses of tamoxifen still worked, hinting that Ivermectin could make resistant cancers sensitive again.

The paper focuses on the Wnt signaling pathway, which is often overactive in breast cancer and drives growth and spread. Ivermectin reduced certain Wnt “signals” (like Wnt5a/b ligands) and a receptor (LRP6), leading to less EMT and potentially slower progression. The effects were stronger in resistant cells. The researchers compared Ivermectin to an approved drug palbociclib (Ibrance), used for similar resistant breast cancers, and found Ivermectin was more effective at blocking some spread-related changes in their tests.

Authors concluded that these insights underscore the potential of repurposing IVM (ivermectin) for endocrine-resistant breast cancer patients.

Metastatic Triple Negative Breast Cancer (mTNBC)

In 2020 (Juarez et al) - Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. Ivermectin was tested at 2mg/kg/day which translates to roughly 5uM in vitro concentration. The most sensitive cancer cell lines include Ovarian, Breast and breast TNBC. Ivermectin was also found to be synergistic with docetaxel, cyclophosphamide and tamoxifen.
Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited.

Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. (Nature 2021)

There are more than 800 clinical trials of ClinicalTrials.gov on metastatic triple negative breast cancer.

Related Updates: 

18. Conclusion

In conclusion, fenbendazole, ivermectin, and mebendazole present promising low-cost, widely accessible options in breast cancer management. Their integration into clinical practice demands coordinated research efforts, greater oncologist- integrative practitioner collaboration, and patient-centered care models. This evolving paradigm holds potential to expand therapeutic horizons for patients with limited options and underscores the critical need for innovation in cancer treatment.

The 130-case breast-cancer archive contains a heterogeneous collection of reported experiences involving ivermectin, mebendazole, fenbendazole and combinations of these agents with conventional oncology treatments.

When reorganized into clinical patterns and sub-patterns, several recurring signals emerge: primary-tumor regression, nodal regression, bone response, visceral response, CNS response, biomarker improvement, pathological response and symptomatic improvement.

However, the dominant methodological limitation is causal ambiguity. In many of the most striking cases, several therapies were administered simultaneously. Consequently, the archive cannot determine whether the repurposed drug, conventional therapy, treatment interaction, natural disease variation or another intervention produced the observed response.

The appropriate scientific conclusion is therefore neither dismissal nor proof. The cases should be treated as a hypothesis-generating clinical signal set.

The next step is not more testimonials. The next step is better data.

In a broader context, emerging 2026 evidence on insulin resistance and cancer risk, together with growing evidence linking higher ultra-processed food consumption to poorer health and cancer outcomes, and new research on dietary preservatives, strengthens the case that nutrition should not be dismissed as a mere “lifestyle nicety.” Rather, diet quality and metabolic health should be regarded as foundational components of cancer prevention and supportive care—alongside, not instead of, evidence-based oncologic treatment.

For a more comprehensive understanding, it's worth looking into additional research studies and clinical trials. As always, consult with your healthcare provider(s) before making any treatment decisions, as close monitoring and personalised care are essential.

Notes:

No single drug is a miracle cure for all cancers. Taking a particular drug as a stand alone strategy cannot replace an unhealthy lifestyle i.e. heavy smoker, alcoholic, a very stressful and non-active lifestyle, overweight and obesity. All these cancer promoting factors need to change.

The best way to fight cancer is to utilise a menu of strategies by maintaining good health, like from eating a nutritious whole-food diet with lots of fruits and vegetables, avoid ultra processed foods and a healthy lifestyle. Each strategy might produce an incremental improvement in results for some cancers when added to existing treatment regimens.

Everyone’s situation is different, however, it is important to arm yourself with medical knowledge that cancer doctors (Oncologists) may simply not give you.

Whether you’re living with cancer or a survivor, talk to your doctor to determine the best treatment for you.

For an evidence-graded overview of repurposed cancer drugs, see our full guide.

Editorial Evidence Statement

This page distinguishes between reported observations and established evidence. The case archive should not be described as a clinical trial, systematic review or proof-of-efficacy study. The term "case series" refers to the organized collection of individual case narratives; it does not imply prospective enrollment, independent verification or uniform diagnostic criteria.

Future versions should progressively replace testimonial-level evidence with independently verified case reports, prospective registries and randomized clinical trials.


    Frequently Asked Questions

    Are ivermectin, mebendazole or fenbendazole proven breast-cancer treatments?

    The available case narratives are hypothesis-generating and do not establish efficacy through randomized controlled trials.

    Why analyze 130 cases if they are not clinical trials?

    Because repeated case patterns can identify potentially important hypotheses. The purpose of the classification is to determine whether similar response phenotypes recur and which cases deserve formal investigation.

    Can the responses be attributed to ivermectin or mebendazole?

    Often they cannot. Many patients simultaneously received chemotherapy, endocrine therapy, targeted therapy, immunotherapy or other interventions.

    Are any cases more convincing than others?

    Yes. Cases with biopsy confirmation, serial imaging, surgical pathology and independent documentation are more informative than unverified testimonials. However, even a compelling individual case cannot establish population-level efficacy.

    Why is triple-negative breast cancer an important subgroup?

    TNBC lacks ER, PR and HER2 expression and has fewer conventional targeted options than many other breast-cancer subtypes. It therefore represents an important area for clinical research into new treatment combinations.

    Does tumor-marker reduction prove that cancer was eliminated?

    No. Biomarker changes are supportive information and should be interpreted alongside imaging, pathology and clinical outcomes.

    What should researchers do next?

    The most informative next step would be prospective studies with standardized eligibility criteria, treatment documentation, imaging, pathology, biomarkers, adverse-event reporting and predefined endpoints.


    References:

    1. Bianchini G, et al. Nat Rev Clin Oncol. 2016;13(11):674–690.
    2. Dent R, et al. Clin Cancer Res. 2007;13(15 Pt 1):4429–4434.
    3. Lehmann BD, et al. J Clin Invest. 2011;121(7):2750–2767.
    4. Schmid P, et al. N Engl J Med. 2018;379(22):2108–2121.
    5. Adams S, et al. J Clin Oncol. 2021;39(27):3069–3079.
      6. Cortés J, et al. N Engl J Med. 2022;387(3):217-226. https://www.nejm.org/doi/full/10.1056/NEJMoa2202809 (KEYNOTE-355)
    6. PCCARx Pharmacy. Exploring the Oncology Potential of Mebendazole and Ivermectin. 2025. https://www.pccarx.com/Blog/exploring-the-oncology-potential-of-mebendazole-and-ivermectin-what-compounding-pharmacists-should-know
    7. Draganov et al - Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer (Nature 2021)
    8. Top Repurposed Drugs and Metabolic Interventions for Cancer Treatment
    9. Mebendazole vs fenbendazole for cancer
    10. Ivermectin Tested against 28 types of Cancer: Most Sensitive vs Least Sensitive
    11. Fenbendazole and Ivermectin for Cancer: The Ultimate 2026 Guide (OneDayMD 2026)
    12. Fenbendazole and Other Stage 4 Cancer Types: The compilation includes over 300 stage 4 cancer case reports across 17 cancer types. Full details are provided in the following: Stage 4 Cancer Remissions with Fenbendazole, Ivermectin and Mebendazole (February 2026 Edition).
    13. Fenbendazole, Ivermectin and Mebendazole Cancer Success Stories: 700+ Case Reports Compilation of various stages (stages 1 to 4) of different cancer types. (One Day MD 2026)
    14. Targeting obesity-related dysfunction in hormonally driven cancers (Nature 2021).
    15. From Cancer to Victory: One Woman’s Journey to Health and Resilience - Dr Kelly Victory 
    16. Rujimongkon K, Adchariyasakulchai P, Boonyaratsewee C, Horpratraporn K, Ketchart W (2026) Ivermectin inhibits ER, HER2, and TGF-β pathways in ER-positive and endocrine-resistant breast cancer cells. PLoS One 21(4): e0348260. https://doi.org/10.1371/journal.pone.0348260
    17. Case-level source material: OneDayMD, "Ivermectin and Mebendazole for Breast Cancer: A Case Series of 130 Case Reports" (August 2026 update), and the public social media/Substack posts cited therein.
    Follow us for more updates on Substack.


    Medical Disclaimers:
    • Statements on this website have not been evaluated by the Food and Drug Administration. The contents of this website is for educational and informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis or treatment.
    • This article is an evidence-analysis and case-classification resource. It is not medical advice and does not recommend self-treatment with ivermectin, mebendazole, fenbendazole or any other non-standard cancer therapy.
    • Please do not consider this guide as personal medical advice, but as a recommendation for use by professional providers. Consult with your doctor and discuss with her/him. Our aim here isn't to replace your doctors' advice. It is intended as a sharing of knowledge and information. Do take note that cancer is a continuous struggle between the immune system and the cancer cells. Cancer treatments are meant to assist the immune system in this battle. Any potential treatment—whether conventional or complementary—must be evaluated on a case-by-case basis, with careful consideration of the benefit-risk ratio to ensure both safety and efficacy.
    • The case reports presented reflect the real-life experiences and opinions of other readers or users of the website. The experiences of those readers or users are personal to those particular readers/users and may not necessarily be representative of all readers/users. We do not claim, and you should not assume, that all other readers/users will have the same experiences. Do you own research, consult with relevant medical professionals before attempting to self-treat for any condition.
    • Cancer care is a team effort with the patient at the centre. Care should be supervised and coordinated by a primary healthcare provider. Patients with cancer should consult with their regular oncologist as well as an integrative provider/oncologist, in addition to their primary care provider and the supporting nurses, dieticians and other allied healthcare professionals.
    • Caution: Do not self-medicate. Always discuss any treatment with a trusted healthcare professional. Self-medication can carry serious risks, including liver toxicity and drug interactions. For the best outcomes, any treatment should be integrated into a personalized care plan that considers the whole person—not just the disease—and includes appropriate medical supervision and ongoing monitoring.

    Comments

    Post a Comment

    Popular posts from this blog

    Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

    Image
    Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. Supporters point to hundreds of preclinical studies and case reports showing anti-tumor activity across multiple cancer types.  However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiotherapy. So where does the truth lie? The answer is more nuanced than either side often suggests. Access to modern cancer care remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings m...
    Read more

    Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

    Image
    Medically Reviewed | Last updated on June 28, 2026. Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. Repurposed Cancer Therapies Case Reports Explorer Interactive tracking dashboard compiling 766 reported case studies across 21 fields. Click any card to jump directly to its dedicated arti...
    Read more

    Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

    Image
    Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
    Read more

    Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

    Image
    Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
    Read more

    Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

    Image
    Quick Answer The supplements with the strongest human research behind them are vitamin D3 (paired with K2 and magnesium) , curcumin , omega-3 fatty acids , and green tea EGCG — each backed by multiple randomized controlled trials or meta-analyses, though results are mixed rather than uniformly positive. Melatonin looked promising in older, smaller trials, but the largest randomized trial to date found no overall survival benefit. No supplement replaces conventional cancer treatment, and a few — high-dose beta-carotene, vitamin E, and high-dose B6/B12 — have been linked to increased cancer risk in specific groups. Antioxidant supplements are generally discouraged during chemotherapy or radiotherapy unless a doctor directs otherwise. This is an educational overview, not personal medical advice — always loop in your oncology team before starting anything new. Disclosure: Some links in this article are affiliate links (including The Wellness Company and Amazon Associates). If ...
    Read more

    Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

    Image
    Last revised: July 2026 .  Integrative Oncology · Protocol Review A comprehensive synthesis of Dr Makis's clinical dosing regimens, benzimidazole combination strategies, the 2026 Hulscher observational cohort, pharmacokinetic rationale, safety monitoring requirements, and anonymised patient outcome data — presented with evidence grading. OneDayMD Editorial Team  |  Medically reviewed and updated  |  About Us Abstract Background: Dr William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has treated cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centres on high-dose ivermectin combined with benzimidazoles and metabolic interventions, customised by cancer type and stage. Purpose: This continuously updated review synthesises Dr Makis's published p...
    Read more

    Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

    Image
    Medically Reviewed by: OneDayMD Editorial Team | Evidence Synthesis & Safety Review | Last Updated: August 2026 Quick Answer Ivermectin, fenbendazole, and mebendazole are antiparasitic drugs with laboratory evidence of anticancer activity.  The pharmacological rationale is real and merits continued, properly controlled trial investment. Patients should discuss any interest in these agents openly with their oncology team rather than self-administering veterinary or compounded formulations.  This article separates the genuine research question from the unverified claims, and outlines what to discuss with an oncology team before considering any of these agents. Background: Ivermectin and the benzimidazole anthelmintics fenbendazole and mebendazole have attracted sustained public attention as repurposed anticancer agents, driven substantially by social media case testimonials and a small number of peer-reviewed mechanistic studies. Objective: To synthesize the precl...
    Read more

    Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

    Image
    Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
    Read more

    30 Best Alternative Cancer Treatments: Evidence Based Literature Review (2026 Update)

    Image
    Updated August 2026 · Evidence-Ranked Edition This article has been reorganised to rank all 30 integrative cancer interventions by the quality and quantity of available evidence — from randomised controlled trial data down to preclinical laboratory findings. Use this as a structured reference, not a treatment guide. Always consult a qualified healthcare professional before initiating any therapy. ⚠️ Medical Disclaimer: This content is for educational purposes only. Nothing in this article should be used as the basis for initiating, modifying, or discontinuing any cancer treatment without guidance from your treating oncologist or physician. The interventions described here are not approved cancer treatments unless explicitly stated. Diverse cancer hallmarks targeted by repurposed non-oncology drugs. Source: Nature 2024 Introduction Most mainstream guides to “alternative cancer treatments”—including the widely cited Mayo Clinic overview—fo...
    Read more

    Fenbendazole, Ivermectin and Mebendazole for Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2026)

    Image
    OneDayMD  |  Integrative Oncology Review ISSN (Online) pending  •  Volume 1, Issue 1  •  Published: 10 August 2025  •  Last updated: 15 July 2026 Case Series & Mechanistic Review Compiled tumour marker responses, radiologic outcomes, and mechanisms of anti-cancer action across an international patient cohort DOI: pending  •  Cite as: OneDayMD Editorial Team. Antiparasitic Drug Repurposing in Stage 4 PDAC: A Compiled Case Series of 28 Patients. OneDayMD Integr Oncol Rev. 2025;1(1). Updated July 2026. Evidence Classification All case reports in this series represent CEBM Level 4–5 evidence (case reports and expert opinion). This compilation is hypothesis-generating. No randomised controlled trials of ivermectin, fenbendazole, or mebendazole for pancreatic cancer have been published as of July 2026. ...
    Read more